Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity
Autore:
Oleandri, SE; Maccario, M; Rossetto, R; Procopio, M; Grottoli, S; Avogadri, E; Gauna, C; Ganzaroli, C; Ghigo, E;
Indirizzi:
Univ Turin, Dipartimento Med Interna, Div Endocrinol, I-10124 Turin, ItalyUniv Turin Turin Italy I-10124 rna, Div Endocrinol, I-10124 Turin, Italy Osped S Croce, Div Endocrinol, Cuneo, Italy Osped S Croce Cuneo ItalyOsped S Croce, Div Endocrinol, Cuneo, Italy Osped SS Annunziata, Div Med Interna, Savigliano, Italy Osped SS Annunziata Savigliano Italy Div Med Interna, Savigliano, Italy
Titolo Testata:
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
fascicolo: 2, volume: 22, anno: 1999,
pagine: 134 - 140
SICI:
0391-4097(199902)22:2<134:TTWMOD>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH FACTOR-I; DEHYDROEPIANDROSTERONE-SULFATE; INSULIN RESISTANCE; D-FENFLURAMINE; ANDROID OBESITY; HORMONE RELEASE; SOMATOMEDIN-C; RISK-FACTORS; WOMEN; GLUCOSE;
Keywords:
obesity; metformin; dexfenfluramine; glucose; insulin; IGF-I; DHEA-S; blood pressure;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Ghigo, E Osped Molinette, Div Endocrinol, Cso Dogliotti 14, I-10126 Turin,Italy Osped Molinette Cso Dogliotti 14 Turin Italy I-10126 urin, Italy
Citazione:
S.E. Oleandri et al., "Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity", J ENDOC INV, 22(2), 1999, pp. 134-140

Abstract

Abdominal obesity is connoted by hyperinsulinism and insulin insensitivity, a trend toward glucose intolerance, hypoactivity of GH/IGF-I axis and alterations of hypothalamo-pituitary-adrenal (HPA) axis. It has been hypothesized that treatment with metformin (MET) and dexfenfluramine (DEX) could counteract those endocrine-metabolic alterations. Thus, we studied the effectsof 3-month treatment with MET or DEX on anthropometric (BMI, WHR, FM and FFM), metabolic (basal and OGTT-induced glucose) and hormonal variables (IGF-I, DHEA-S, androstendione, testosterone, fT3, fT4, TSH, basal and OGTT-induced insulin) as well as on blood pressure in 28 normotensive patients withabdominal obesity (OB, 3 M, 25 F; 47.5+/-1.5 yr [mean+/-SE], BMI 35.4+/-1.1 kg/m(2), WHR 0.98+/-0.04 and 0.86+/-0.07, in M and F, respectively). All patients were on balanced hypocaloric diet (1400 Kcal/day). Patients were randomly assigned to treatment with MET (no.=10, 500 mg twice daily po) or DEX (no.=10, 15 mg thrice daily po) or placebo (no.=8). Before treatment allgroups had similar anthropometric, metabolic and hormonal values. After 3-month treatment with MET, DEX or placebo, weight, BMI and WHR reductions were similar in all groups (p<0.05 vs baseline in either group). In each group FFM/FM ratio showed non significant trend toward increase. No significantvariations in metabolic and endocrine variables were recorded in each group after 1 and 3-month treatment. However, glucose tolerance, OGTT-induced insulin response, glucose/insulin ratio showed a similar trend toward improvement in all groups, white IGF-I, 24 h urinary cortisol, DHEA-S, androstendione, testosterone, thyroid hormone and TSH levels did not show any variation. Significant (p<0.02) and similar reductions of DBP, but not of SEP, levers were found in all groups. In conclusion, our findings demonstrate that,at least after 3-month treatment, metformin and dexfenfluramine do not modify the effects of diet on anthropometric, metabolic and hormonal parameters as well as on blood pressure in patients with abdominal obesity. (C) 1999, Editrice Kurtis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 22:26:41